Pharmsville KRX:318010KOSDAQ
팜스빌 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, Pharmsville reported revenue of ₩2.4bn, down 28.6% year on year, and an operating loss of ₩162m. Pharmsville (팜스빌) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 22 with 1 article.
Filing signals Swung to loss 4 quarters of losses Screener
Pharmsville quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.4bn | -28.6% | −₩162m margin −6.8% | ₩475m |
| Q1 2026 | ₩2.5bn | -25.5% | −₩55m margin −2.2% | ₩1.2bn |
| Q4 2025 derived | ₩3.0bn | -17.6% | −₩351m margin −11.9% | ₩831m |
| Q3 2025 | ₩3.4bn | -20.7% | −₩119m margin −3.5% | ₩500m |
| Q2 2025 | ₩3.3bn | -18.4% | ₩89m margin 2.7% | ₩1.1bn |
| Q1 2025 | ₩3.3bn | -30.4% | ₩89m margin 2.7% | ₩1.1bn |
| Q4 2024 derived | ₩3.6bn | -25.0% | −₩184m margin −5.1% | ₩950m |
| Q3 2024 | ₩4.2bn | -20.8% | −₩213m margin −5.0% | ₩245m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Pharmsville top stories 2 weeks, by number of outlets
- 1